Umbilical cord blood may help build heart valves

By Michael Kahn

LONDON (Reuters) - Doctors may one day be able to use stem cells taken from umbilical cord blood to build new heart valves for children born with heart defects, German scientists said on Monday.

These valves could grow as a child develops, doing away with any need for repeated operations to replace outgrown artificial valves or valves made from animal or human donor tissue, said Ralf Sodian of University Hospital Munich, who led the study.

“The problem is if you have to do surgery on a child you have a relatively small heart valve and the child grows out of it, which means you have to do the surgery many times,” Sodian said in a telephone interview.

“The basic idea is to implant something living, functional from your own cells which will integrate into the surrounding tissue with the potential to grow.”

Stem cells are the body’s master cells and there are several kinds. Stem cells from the bone marrow or cord blood are partly differentiated, or transformed, and can be used to restore the immune systems of patients undergoing cancer treatment, for example.

Tissue engineering of heart valves is still in its infancy, with different research teams looking at whether it is possible to use stem cells, bone marrow or amniotic fluid.

When infants have faulty heart valves that cannot be surgically repaired, they rely on replacement from animal tissue, donated human organs or artificial materials.

In what is called a concept study, Sodian and colleagues showed it was possible to collect blood from the umbilical cord at birth, harvest the stem cells and then make a heart valve that is ready when the baby needs it.

“We showed it is possible to do this with human cells,” said Sodian, whose research was presented at the American Heart Association Meeting in New Orleans.

To do this, the researchers first extracted and then froze the cord blood to preserve the cells. After 12 weeks, they seeded the cells onto eight biodegradable heart valve scaffolds and grew them in the laboratory.

Examination using electron microscopes showed the cells had grown into the pores of the scaffolding and formed a tissue layer. Further tests indicated the cells were heart tissue.

While the technique shows promise, Sodian cautioned that researchers need to work out several issues before they can think about attempting it in people.

“Tissue engineering provides the prospect of an ideal heart valve substitute that lasts throughout the patient’s lifetime and has the potential to grow with the recipient and to change shape as needed,” he added in a statement.

(Reporting by Michael Kahn; Editing by Maggie Fox and Michael Roddy)


Related Posts:

WASHINGTON (Reuters) - The U.S. Food and Drug Administration has cleared the way for the world’s first study of human embryonic stem cell therapy, Geron Corp said on Friday. The California biotechnology company plans to start a clinical trial to try to use the stem cells to regrow nerve tissue in patients with acute spinal cord

Full Post: FDA allows first test of human stem cell therapy

By Julie Steenhuysen CHICAGO (Reuters) - U.S. scientists have created the first human model for studying a devastating nerve disease, which allows them to watch how the disease develops and could help researchers find a way to treat it. Using skin cells from a child with spinal muscular atrophy, a genetic disease that attacks motor neurons in

Full Post: U.S. scientists recreate nerve disease to study it

By Michael Kahn LONDON (Reuters) - A novel drug combination using Genzyme Corp’s Mozobil shows it may be possible to spur bone marrow into releasing extra adult stem cells into the bloodstream to repair the heart and broken bones, researchers said on Thursday. The study of mice raises hope that researchers could use the same technique to

Full Post: New drug combo may boost stem cell production

By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - Researchers trying to find ways to transform ordinary skin cells into powerful stem cells said on Sunday they found a shortcut by “sprinkling” a chemical onto the cells. Adding the chemical allowed the team at the Harvard Stem Cell Institute in Massachusetts to use just two genes

Full Post: Researchers find easier way to make stem cells

LONDON (Reuters) - European regulators on Thursday ruled against allowing a patent on developing human embryonic stem cells, a decision that could stifle research by stem cell companies for commercial purposes. An appeal panel at the European Patent Office upheld a June decision to reject a patent application regarding the use of stem cells filed by

Full Post: European agency rules against stem cell patents

Site Navigation

Most Read